Mesenchymal cells in the Lung: Evolving concepts and their role in fibrosis
Gene · 2023-04 · 859 · 147142
DOI: 10.1016/j.gene.2022.147142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gene, 2023-04. Verfasst von Giovanni Ligresti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston MA, US. Electronic address: ligresti@bu.edu. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Mesenchymal Stem Cells, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 289 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Mesenchymal cells in the lung are crucial during development, but also contribute to the pathogenesis of fibrotic disorders, including idiopathic pulmonary fibrosis (IPF), the most common and deadly form of fibrotic interstitial lung diseases. Originally thought to behave as supporting cells for the lung epithelium and endothelium with a singular function of producing basement membrane, mesenchymal cells encompass a variety of cell types, including resident fibroblasts, lipofibroblasts, myofibroblasts, smooth muscle cells, and pericytes, which all occupy different anatomic locations and exhibit diverse homeostatic functions in the lung. During injury, each of these subtypes demonstrate remarkable plasticity and undergo varying capacity to proliferate and differentiate into activated myofibroblasts. Therefore, these cells secrete high levels of extracellular matrix (ECM) proteins and inflammatory cytokines, which contribute to tissue repair, or in pathologic situations, scarring and fibrosis. Whereas epithelial damage is considered the initial trigger that leads to lung injury, lung mesenchymal cells are recognized as the ultimate effector of fibrosis and attempts to better understand the different functions and actions of each mesenchymal cell subtype will lead to a better understanding of why fibrosis develops and how to better target it for future therapy. This review summarizes current findings related to various lung mesenchymal cells as well as signaling pathways, and their contribution to the pathogenesis of pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston MA, US. Electronic address: ligresti@bu.edu.
- Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston MA, US.
- Department of Physiology & Biomedical Engineering, Mayo Clinic, Rochester, MN, US.
- Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, US.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Ligresti, G., Raslan, A. A., Hong, J., Caporarello, N., Confalonieri, M., & Huang, S. K. (2023). Mesenchymal cells in the Lung: Evolving concepts and their role in fibrosis. Gene, 859, 147142. https://doi.org/10.1016/j.gene.2022.147142
Vancouver
Ligresti G, Raslan AA, Hong J, Caporarello N, Confalonieri M, Huang SK. Mesenchymal cells in the Lung: Evolving concepts and their role in fibrosis. Gene. 2023;859:147142. doi:10.1016/j.gene.2022.147142
BibTeX
@article{Ligresti2023,
author = {Ligresti, Giovanni and Raslan, Ahmed A and Hong, Jeongmin and Caporarello, Nunzia and Confalonieri, Marco and Huang, Steven K},
title = {Mesenchymal cells in the Lung: Evolving concepts and their role in fibrosis},
journal = {Gene},
year = {2023},
volume = {859},
pages = {147142},
doi = {10.1016/j.gene.2022.147142}
}
EUVIMED